Drug Profile

Capmatinib - Novartis Oncology

Alternative Names: INC-280; INCB-028060; INCB-28060; TABRECTA; Tabrecta

Latest Information Update: 11 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Developer Array BioPharma; Novartis Oncology
Class Antineoplastics; Benzamides; Fluorobenzenes; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
Mechanism of Action Proto-oncogene protein c-met inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Non-small cell lung cancer
New Molecular Entity Yes

Marketed Non-small cell lung cancer
Phase II Glioblastoma; Liver cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
Phase I/II Breast cancer; Colorectal cancer; Head and neck cancer
No development reported Triple negative breast cancer

29 Nov 2024 Novartis Pharmaceuticals terminates phase-II clinical trials in Non-small cell lung cancer (Adjuvant therapy, Neoadjuvant therapy, Late-stage disease) in USA (PO) due to recruitment challenges (NCT04926831)
27 Nov 2024 Novartis and M.D. Anderson Cancer Center terminates a phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Recurrent) in USA (PO), as the sponsor withdrew he support (NCT05243641)
31 Oct 2023 Novartis completes the phase-III GeoMETry-III trial in Non-small cell lung cancer in Belgium, Germany, Brazil, Bulgaria, France, India, Italy, South Korea, Netherlands, Hungary, Lithuania, Portugal and Spain (PO) (NCT04427072) (EudraCT2020-001578-31)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com